VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Trivalent hepatitis B (HepB) vaccine yields superior seroprotection rates in adults: results from the phase 3...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its previously announced underwritten public offering of 70,000,000 common shares, at a public offering price...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common shares. VBI also intends to grant the...
Read More
VBI is the first biopharma company to collaborate with GSK to assess AS01B adjuvant system as part of a therapeutic cancer vaccine candidate Combination will be tested in additional study arm in Part B of VBI’s ongoing Phase 1/2a clinical...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York City...
Read More
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019 ASCO presentation illustrated encouraging data from Part A of the ongoing...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA, on Thursday, August...
Read More
Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients Initial immunologic data from Part B expected around year-end 2019 Expanded immunologic data and tumor and clinical responses expected...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000® and the Russell 3000® Indexes following the annual reconstitution, effective after the...
Read More